公开(公告)号：US20220000861A1

公开(公告)日：2022-01-06

申请号：US17197725

申请日：2021-03-10

Applicant: OTSUKA PHARMACEUTICAL CO., LTD.

Inventor： Tsuyoshi HIROSE ,  Kenji MAEDA ,  Tetsuro KIKUCHI ,  Masafumi TODA

IPC: A61K31/496 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/15 ,  A61K31/165 ,  A61K31/343 ,  A61K31/381 ,  A61K31/4525 ,  A61K31/5513 ,  A61K45/06 ,  A61K9/20

Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.

公开(公告)号：US20200368227A1

公开(公告)日：2020-11-26

申请号：US16992551

申请日：2020-08-13

Applicant: OTSUKA PHARMACEUTICAL CO., LTD. ,  H. LUNDBECK A/S

Inventor： Kenji MAEDA ,  Mai NAKAMURA

IPC: A61K31/496 ,  A61K31/485

Abstract: A medicament comprising (I) brexpiprazole or a pharmaceutically acceptable salt thereof, and (II) nalmefene or a pharmaceutically acceptable salt thereof in combination, wherein brexpiprazole or a pharmaceutically acceptable salt thereof, and nalmefene or a pharmaceutically acceptable salt thereof are contained in a single preparation, or a pharmaceutical composition containing brexpiprazole or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing nalmefene or a pharmaceutically acceptable salt thereof are formulated for use in combination. The medicament is used for the prophylaxis or treatment of a substance-related disorder, preferably an alcohol-related disorder.

公开(公告)号：US20170258787A1

公开(公告)日：2017-09-14

申请号：US15471429

申请日：2017-03-28

Applicant: OTSUKA PHARMACEUTICAL CO., LTD.

Inventor： Shinji SATO ,  Kenji MAEDA ,  Dai ISHIKAWA ,  Mai NAKAMURA

IPC: A61K31/496

CPC classification number: A61K31/496

Abstract: The present invention relates to a prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease, which contains 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient.

公开(公告)号：US20220370442A1

公开(公告)日：2022-11-24

申请号：US17869993

申请日：2022-07-21

Applicant: OTSUKA PHARMACEUTICAL CO., LTD.

Inventor： Shinji SATO ,  Kenji MAEDA ,  Dai ISHIKAWA ,  Mai NAKAMURA

IPC: A61K31/496

Abstract: The present invention relates to a prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease, which contains 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient.

公开(公告)号：US20190151309A1

公开(公告)日：2019-05-23

申请号：US16250548

申请日：2019-01-17

Applicant: OTSUKA PHARMACEUTICAL CO., LTD. ,  H. LUNDBECK A/S

Inventor： Kenji MAEDA ,  Mai NAKAMURA

IPC: A61K31/496 ,  A61K31/485

Abstract: A medicament comprising (I) brexpiprazole or a pharmaceutically acceptable salt thereof, and (II) nalmefene or a pharmaceutically acceptable salt thereof in combination, wherein brexpiprazole or a pharmaceutically acceptable salt thereof, and nalmefene or a pharmaceutically acceptable salt thereof are contained in a single preparation, or a pharmaceutical composition containing brexpiprazole or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing nalmefene or a pharmaceutically acceptable salt thereof are formulated for use in combination. The medicament is used for the prophylaxis or treatment of a substance-related disorder, preferably an alcohol-related disorder.

公开(公告)号：US20170100395A1

公开(公告)日：2017-04-13

申请号：US15386289

申请日：2016-12-21

Applicant: OTSUKA PHARMACEUTICAL CO., LTD.

Inventor： Tsuyoshi HIROSE ,  Kenji MAEDA ,  Tetsuro KIKUCHI ,  Masafumi TODA

IPC: A61K31/496 ,  A61K45/06 ,  A61K9/20

CPC classification number: A61K31/496 ,  A61K9/20 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/15 ,  A61K31/165 ,  A61K31/343 ,  A61K31/381 ,  A61K31/4525 ,  A61K31/5513 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.

公开(公告)号：US20190314367A1

公开(公告)日：2019-10-17

申请号：US16456334

申请日：2019-06-28

Applicant: OTSUKA PHARMACEUTICAL CO., LTD.

Inventor： Shinji SATO ,  Kenji MAEDA ,  Dai ISHIKAWA ,  Mai NAKAMURA

IPC: A61K31/496

Abstract: The present invention relates to a prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease, which contains 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient.

公开(公告)号：US20180325894A1

公开(公告)日：2018-11-15

申请号：US16041246

申请日：2018-07-20

Applicant: OTSUKA PHARMACEUTICAL CO., LTD.

Inventor： Tsuyoshi HIROSE ,  Kenji MAEDA ,  Tetsuro KIKUCHI ,  Masafumi TODA

IPC: A61K31/496 ,  A61K9/20 ,  A61K31/343 ,  A61K31/5513 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/15 ,  A61K31/165 ,  A61K31/4525 ,  A61K31/381 ,  A61K45/06

CPC classification number: A61K31/496 ,  A61K9/20 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/15 ,  A61K31/165 ,  A61K31/343 ,  A61K31/381 ,  A61K31/4525 ,  A61K31/5513 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected form the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracycline antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination

公开(公告)号：US20240156811A1

公开(公告)日：2024-05-16

申请号：US18455757

申请日：2023-08-25

Applicant: OTSUKA PHARMACEUTICAL CO., LTD.

Inventor： Tsuyoshi HIROSE ,  Kenji MAEDA ,  Tetsuro KIKUCHI ,  Masafumi TODA

IPC: A61K31/496 ,  A61K9/20 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/15 ,  A61K31/165 ,  A61K31/343 ,  A61K31/381 ,  A61K31/4525 ,  A61K31/5513 ,  A61K45/06

CPC classification number: A61K31/496 ,  A61K9/20 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/15 ,  A61K31/165 ,  A61K31/343 ,  A61K31/381 ,  A61K31/4525 ,  A61K31/5513 ,  A61K45/06

Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (1) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.

公开(公告)号：US20180042923A1

公开(公告)日：2018-02-15

申请号：US15788102

申请日：2017-10-19

Applicant: OTSUKA PHARMACEUTICAL CO., LTD.

Inventor： Tsuyoshi HIROSE ,  Kenji MAEDA ,  Tetsuro KIKUCHI ,  Masafumi TODA

IPC: A61K31/496 ,  A61K31/343 ,  A61K31/5513 ,  A61K31/135 ,  A61K45/06 ,  A61K31/138 ,  A61K31/15 ,  A61K31/165 ,  A61K31/4525 ,  A61K31/381 ,  A61K9/20 ,  A61K31/137

CPC classification number: A61K31/496 ,  A61K9/20 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/15 ,  A61K31/165 ,  A61K31/343 ,  A61K31/381 ,  A61K31/4525 ,  A61K31/5513 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophea-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.